UAE initiates Sinopharm vaccine study for children aged 3-17

UAE initiates Sinopharm vaccine study for children aged 3-17

The UAE's Ministry of Health and Prevention (MoHAP) has announced that it has initiated a Sinopharm immune bridge study for children aged 3 to 17. The UAE is the first country in the Middle East and North Africa region to conduct a study of the vaccine's effectiveness for this age group. The Department of Health - Abu Dhabi has approved the study to be conducted, under the supervision of the health ministry. The study aims to monitor the immune response to the vaccine in 900 children of different nationalities. Each child will participate with the full consent of their parents and be closely monitored. Parents and children will be given details and support at every step of the process, reported. Dr Nawal Al Kaabi, chairwoman of the National Covid-19 Clinical Management Committee, who is leading the study, said: "As more and more people are vaccinated in the UAE, we want to make sure that our children are able to receive the vaccine safely. This is why when we designed the Sinopharm immune bridge study we focused on ensuring all care is given to our young volunteers throughout the journey. We want both children and parents to understand every step of